Patients Using Wellness Peptides Have No Reliable Information About Whether They Are Safe or Effective, ECRI and ISMP Warn

New joint white paper asserts commercial market for compounded peptide products has outpaced the clinical evidence; unless the product is explicitly FDA-approved, there is insufficient evidence of its safety or efficacy. WILLOW GROVE, Pa., May 5, 2026 /PRNewswire/ -- ECRI and the...